Informations générales (source: ClinicalTrials.gov)
Effectiveness of a Patient Therapeutic Education Program in Improving Pain Management (EFFADOL-K)
Observational
Centre Francois Baclesse (Voir sur ClinicalTrials)
décembre 2017
décembre 2023
29 juin 2024
Pain is one of the most feared and burdensome symptoms experienced by cancer patients.
Its prevalence has been estimated by INCa1 in 2012 at 48% in patients undergoing cancer
treatment, and unrelieved pain is directly associated with significantly reduced quality
of life (QoL)2. A large part of cancer pain undertreatment can be attributed to
patient-related barriers. Patient barriers are multifactorial and often result from a
lack of knowledge about cancer pain and its self-management. They mainly consist of
misconceptions about opioids and their side effects, nonadherence, and reluctance to
alert health care providers to unrelieved pain. Patient education enables people with
chronic disease to manage their illness, and has been considered in the field of cancer
research as an important strategy to achieve optimal pain control.
In Basse-Normandie french region, the "Health Regional Plan, pain aspect" has identified
the theme " pain education program " as a priority.
The main endpoint is the decrease of pain interference with daily life (using the Brief
Pain Inventory). The experimental group, consisting of cancer pain patients, will benefit
from the education program by previously trained health care providers. It will be
compared with the control group, consisting with patients whose pain will be
conventionally managed before the professional training in therapeutic education.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Sophie LAURENT | 07/08/2023 15:06:19 | Contact (sur clinicalTrials) | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Europeen Georges Pompidou | Alexandre SAADI, MD | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre François Baclesse - Caen - France | Contact (sur clinicalTrials) | ||||
| centre Hospitalier d'Alençon - Alençon - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier d'Argentan - Argentan - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier de Saint-lo - Saint-Lô - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier Lisieux - Lisieux - France | Virith SEP HIENG, MD | Contact (sur clinicalTrials) | |||
| Ch Dieppe - Dieppe - France | Anne-Laure QUESNEL, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Hospitalier AVRANCHES-GRANVILLE - Avranches - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier Bayeux - Bayeux - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier de Cherbourg - Cherbourg-Octeville - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier de Flers - Flers - France | Contact (sur clinicalTrials) | ||||
| CHU CAEN - Caen - France | Marjorie LOAEC, MD | Contact (sur clinicalTrials) | |||
| Ghpso Senlis - Senlis - France | Gwladys FONTAINE, MD | Contact (sur clinicalTrials) | |||
| Hopital privé Paul d'Egine - Champigny-sur-Marne - France | Freddy KAYEMBE, MD | Contact (sur clinicalTrials) | |||
| IGR - Villejuif - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Patient suffering from a cancer which diagnosis has been established since at least
1 month
- Patient who suffers from pain related to the pathology or its treatment:
- receiving an analgesic treatment since at least 1 month
- moderate to severe pain intensity in the previous week : average pain score greater
than 4 (on a 0-10 numerical rating scale), OR pain leading to insomnia OR 4 daily
breakthrough pain, which interferes with daily activities
- Patient with a life expectancy > or = 6 months
- Health compatible with the PEP requirements (WHO performance scale > or = 2)
- Patient v 18 years old
- Patient able to understand, speak and read French
- Patient without cognitive dysfunctions
- Patient with a signed informed consent before inclusion in the study
- Patient suffering from a cancer which diagnosis has been established since at least
1 month
- Patient who suffers from pain related to the pathology or its treatment:
- receiving an analgesic treatment since at least 1 month
- moderate to severe pain intensity in the previous week : average pain score greater
than 4 (on a 0-10 numerical rating scale), OR pain leading to insomnia OR 4 daily
breakthrough pain, which interferes with daily activities
- Patient with a life expectancy > or = 6 months
- Health compatible with the PEP requirements (WHO performance scale > or = 2)
- Patient v 18 years old
- Patient able to understand, speak and read French
- Patient without cognitive dysfunctions
- Patient with a signed informed consent before inclusion in the study
- Primary central nervous system or cerebral metastases
- Disorders of higher functions documented
- Evolutionary psychiatric pathology
- Drug user
- Abuse of alcohol exceeding WHO recommendations
- Refusal of participation